drugset
drugset / Trial / NCT05076851

Neoadjuvant Therapy With Proxalutamide Combined With Androgen Deprivation Therapy（ADT）for High Risk Prostate Cancer

NCT05076851 ↗

Phase 2 Unknown 2 enrolled Hongqian Guo
RandomizedParallel-groupSingle-blindTreatment

Summary

This trial aims to evaluate the efficacy and safety of neoadjuvant therapy with Proxalutamide combined with androgen deprivation therapy（ADT）for High risk prostate cancer ，This trial is A randomized, controlled, double-blind, single center.Treatment cycle is 6 months,

Timeline

Start
2021-06-17
Primary completion
2021-12-31
Completion
2022-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject PRUXELUTAMIDE Small molecule 300 mg Oral

Indications

No indication recorded.